The recent UN Climate Change Conference (COP26) revealed a massive credibility gap between government current policies and their net-zero goals. Even with full implementation of emissions targets set for 2030, the planet is expected to heat up by 2.4°C by the end of the century. This alarming gap has cast a dark shadow of doubt over […]

The post How the Technology Industry Can Speed up Environmental Protection Efforts appeared first on DATAVERSITY.

One third of the companies studied haven't fixed their credential management — the same issue that led to the Colonial Pipeline hack last May.

Data published in the International Journal of Nanobiotechnology Peer-reviewed preclinical data in an anti-PD-1 resistant lung cancer model show that adding NBTXR3 to a combination of radiotherapy, anti-PD-1, and anti-CTLA-4 produced significant antitumor effects against both primary and secondary tumors, improved the mouse survival rate from 0 to 50%, and induced long term antitumor memory […]

The post NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4 appeared first on Fintech News.

The FBI’s Internet Crime Complaint Center (IC3) has issued a flash alert connecting Diavol ransomware to hackers who are behind the Trickbot banking Trojan, according to a notice late last week. The FBI’s cyber division said it first learned of Diavol ransomware in October. Analysts quickly associated the data-encrypting malware with the developers of Trickbot. Trickbot is an […]

Text embeddings are useful features in many applications such as semantic search and computing text similarity. Previous work typically trains models customized for different...

Table of Contents: Which Cryptos Will Survive a Bear Market? Contagion in the Crypto Market Why Choose Cryptos That Will Survive the Bear Market? How to Pick a Balanced Crypto Portfolio Which Cryptos Should You Pick? How to Identify the Best Cryptos How to Conduct Due Diligence on Cryptos Crypto White Paper Analysis The Project […]

TOKYO, Jan 20, 2022 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced the publication of results from the Phase 3 Study 309/KEYNOTE-775 trial in the January 19, 2022 edition of the New England Journal of Medicine. The pivotal study evaluated the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. versus chemotherapy (treatment of physician's choice of doxorubicin or paclitaxel) for patients with advanced endometrial carcinoma following at-least one prior platinum-based regimen in any setting.

The publication includes previously reported data that was first presented in an oral plenary session at the virtual Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer.(1) Results showed that the LENVIMA plus KEYTRUDA combination demonstrated statistically significant improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to chemotherapy. Objective response rate (ORR) data and additional detailed efficacy and safety data, including subgroup analyses, are also featured in the publication.

"While rates of endometrial carcinoma continue to rise globally, patients with advanced or recurrent disease have limited options available to them once the disease progresses following platinum-based chemotherapy," said Dr. Gregory Lubiniecki, Vice President, Oncology Clinical Research, Merck Research Laboratories. "KEYNOTE-775/Study 309 is an important Phase 3 study that supported recent approvals of KEYTRUDA plus LENVIMA for certain types of advanced endometrial carcinoma in the U.S. and other countries around the world, where it became the first immunotherapy and tyrosine kinase inhibitor combination approved for these patients."

"The Phase 3 Study 309/KEYNOTE-775 trial demonstrates the ongoing commitment that Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. share in addressing the unmet needs of people living with difficult-to-treat cancers, including advanced endometrial carcinoma," said Corina Dutcus, M.D., Senior Vice President, Clinical Research, Oncology Business Group at Eisai Inc. "The publication of this study in the New England Journal of Medicine reflects the importance of our joint research in exploring the potential of the LENVIMA plus KEYTRUDA combination."

The publication contains results for the all-comer population, including the mismatch repair deficient (dMMR) patient population for which LENVIMA plus KEYTRUDA is not approved in the U.S.

Based on the results from the Phase 3 Study 309/KEYNOTE-775 trial, LENVIMA plus KEYTRUDA has been approved in the U.S. for patients with advanced endometrial carcinoma that is not microsatellite instability-high or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. LENVIMA plus KEYTRUDA is also approved in the European Union and Japan for certain patients with advanced or recurrent endometrial carcinoma regardless of mismatch repair status. Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. are studying the LENVIMA plus KEYTRUDA combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program in more than 10 different tumor types across more than 20 clinical trials.

(1) Eisai co., Ltd. Home page. "LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 Study". https://www.eisai.com/news/2021/news202116.html

Eisai Co., Ltd.
Public Relations:
+81-(0)3-3817-5120
Investor Relations:
+81-(0) 70-8688-9685

Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Media Relations
Melissa Moody: +1-(215) 407-3536
Nikki Sullivan: +1-(718) 644-0730
Investor Relations
Peter Dannenbaum: +1- (908) 740-1037
Raychel Kruper: +1-(908) 740- 2107

For more information, visit https://www.eisai.com/news/2022/news202207.html.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced the publication of results from the Phase 3 Study 309/KEYNOTE-775 trial in the January 19, 2022 edition of the New England Journal of Medicine.

Prospective entrants to the sector will receive instruction on fundamental cybersecurity concepts on which they will be evaluated during the new (ISC)² entry-level cybersecurity certification pilot exam.

Continue reading at Coinspeaker

We can see that Artificial Intelligence (AI) is transforming many parts of our lives, but do we know where this journey is taking us? Insurers need some certainty on what their future will looks like. Some new insurers are trying new business models enthusiastically and then changing direction sharply, like a speedboat swerving to avoid […]

The post Existing insurers and disruptors are utilizing Artificial Intelligence to create new business models appeared first on Fintech News.

In mid-October 2021, Twitter founder Jack Dorsey revealed the payments firm Block Inc. (formally Square) was considering joining the bitcoin mining industry. Three months later, Dorsey tweeted that his firm was “officially building an open bitcoin mining system.” The Block’s Hardware General Manager: ‘We See Bitcoin Mining as a Long-Term Need for a Future That […]

HongKong, China, 14th January, 2022, Chainwire Credit is not only the cornerstone of the market economy, the credit mechanism has

The post has appeared first on thenewscrypto.com